Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bempedoic acid - Esperion Therapeutics

Drug Profile

Bempedoic acid - Esperion Therapeutics

Alternative Names: ESP-55016; ETC-1002; NEXLETOL; NILEMDO; Nilemdo

Latest Information Update: 05 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Esperion Therapeutics
  • Developer Daiichi Sankyo Europe; Esperion Therapeutics; Otsuka Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Dicarboxylic acids; Fatty acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; ATP citrate (pro S) lyase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type II
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia
  • Registered Cardiovascular disorders
  • Phase I Hypertension

Most Recent Events

  • 29 May 2024 Adverse events and efficacy data from the phase-III CLEAR Outcomes trial in Cardiovascular disorders released by Daiichi Sankyo Company
  • 22 May 2024 Registered for Cardiovascular disorders (Treatment-experienced) in European Union, Iceland, Norway, Liechtenstein (PO)
  • 06 Apr 2024 Adverse events and efficacy data from the phase-III CLEAR Outcomes trial in Cardiovascular disorders presented at the 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top